节拍卡培他滨联合芳香化酶抑制剂作为激素受体阳性、人表皮生长因子受体2阴性转移性乳腺癌初始治疗的III期MECCA试验
MECCA III期随机试验在中国12个中心纳入263例未经系统治疗的激素受体阳性/HER2阴性转移性乳腺癌患者,1:1随机接受节拍卡培他滨联合芳香化酶抑制剂(AI)或单用AI。中位随访50.7个月,联合组中位无进展生存期20.9个月 vs AI组11.9个月(HR 0.58,95%CI 0.43-0.76),联合组中位总生存期未达到 vs AI组45.1个月(HR 0.58,95%CI 0.37-0.93);最常见不良事件为手足综合征和外周神经病变,联合组3级事件发生率15.1%。
要点
- 节拍卡培他滨联合AI较单用AI显著改善HR+/HER2-转移性乳腺癌的PFS和OS。
- 联合组中位PFS 20.9个月 vs AI组11.9个月,HR 0.58(95%CI 0.43-0.76)。
- 联合组中位OS未达到 vs AI组45.1个月,HR 0.58(95%CI 0.37-0.93)。
核心结论
- MECCA试验显示,节拍卡培他滨联合AI一线治疗HR+/HER2-转移性乳腺癌较单用AI显著改善PFS和OS。
- 两种治疗方案的安全性特征均可耐受,与既往报告一致。
研究设计与样本
- 随机III期临床试验,在中国12个中心开展,入组时间为2017年8月22日至2021年9月24日,最终随访日期为2023年8月25日。
- 纳入既往未接受过转移性疾病系统治疗的HR+/HER2-转移性乳腺癌患者,1:1随机分配至节拍卡培他滨联合AI组或单用AI组。
- 共263例患者随机分组,其中254例构成全分析集;主要终点为无进展生存期(PFS),次要终点包括总生存期(OS)、客观缓解率、疾病控制率(定义为疾病控制≥24周)和安全性。
主要发现
- 中位随访50.7个月时,共发生203例PFS事件。
- 节拍卡培他滨联合AI组中位PFS为20.9个月,AI组为11.9个月(HR 0.58,95%CI 0.43-0.76)。
- 联合组中位OS未达到,AI组中位OS为45.1个月(HR 0.58,95%CI 0.37-0.93)。
- 最常见不良事件为手足综合征和外周神经病变;接受联合治疗的患者中3级事件发生率为15.1%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The effects of metronomic chemotherapy plus endocrine therapy have yet to be elucidated through a randomized phase III clinical trial. METHODS: Randomized clinical trials were conducted at 12 centers in China from August 22, 2017, to September 24, 2021, and the final follow-up date was August 25, 2023. Patients with hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC) who had no previous systemic therapy in the metastatic setting were enrolled. Participants were 1:1 assigned to receive either metronomic capecitabine plus an aromatase inhibitor (AI) or AI alone. The primary end point was progression-free survival (PFS). Secondary end points included overall survival (OS), objective response rate, disease control rate (defined as disease controlled for ≥24 weeks), and safety. RESULTS: A total of 263 patients were randomly assigned, among which 254 patients formed the full analysis set. At the median follow-up time of 50.7 months, 203 PFS events occurred. The metronomic capecitabine plus AI arm exhibited a median PFS of 20.9 months compared with 11.9 months in the AI arm (hazard ratio [HR], 0.58 [95% CI, 0.43 to 0.76]). The median OS was not reached in the combination arm and was 45.1 months in the AI arm (HR, 0.58 [95% CI, 0.37 to 0.93]). The most common adverse events were palmar-plantar erythrodysesthesia and peripheral neuropathy; grade 3 events occurred in 15.1% of the patients receiving combination treatment. CONCLUSION: The MECCA trial demonstrated a significant improvement in PFS and OS with first-line metronomic capecitabine plus AI compared with AI alone in patients with hormone receptor-positive+/HER2-negative MBC. Both treatment arms exhibited tolerable safety profiles consistent with previous reports.
引用
- Hong RX, Xu F, Xia W, et al. Metronomic Capecitabine Plus Aromatase Inhibitor as Initial Therapy in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: The Phase III MECCA Trial. J Clin Oncol. 2025. PMID: 39746176. doi:10.1200/JCO.24.00938
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。